This Edition
ARTICLE | Politics, Policy & Law
Congress relying on flawed model to set drug pricing policy
CBO model ignores impact on preclinical biotechs, underestimates effects of price controls on drug development
By Steve Usdin, Washington Editor
August 28, 2021 12:47 AM UTC
Access this Article
Request a Trial
Purchase This Article
Log in
BCIQ Company Profiles
Harvard Business School
Biotechnology Innovation Organization
BCIQ Company Profiles
Harvard Business School
Biotechnology Innovation Organization